EP1379545A2 - Procede de production de series d'anticorps stables regenerables - Google Patents

Procede de production de series d'anticorps stables regenerables

Info

Publication number
EP1379545A2
EP1379545A2 EP02745239A EP02745239A EP1379545A2 EP 1379545 A2 EP1379545 A2 EP 1379545A2 EP 02745239 A EP02745239 A EP 02745239A EP 02745239 A EP02745239 A EP 02745239A EP 1379545 A2 EP1379545 A2 EP 1379545A2
Authority
EP
European Patent Office
Prior art keywords
antibody
protein
arrays
antibodies
producing stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02745239A
Other languages
German (de)
English (en)
Inventor
Jürgen WEHLAND
Ronald Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Publication of EP1379545A2 publication Critical patent/EP1379545A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Definitions

  • the invention relates to a method for producing stable, regenerable antibody arrays using immobilized antibody binding proteins which can specifically recognize the Fc part of antibodies.
  • Arrays with biological test molecules are also called biochips, particularly in miniaturized form. Proven examples of such arrays are:
  • Nucleic acid arrays from DNA fragments, cDNAs, RNAs, PCR products, plasmids, bacteriophages, synthetic oligonucleotides or synthetic PNA oligomers which are read out by means of hybridization (formation of a double-stranded molecule) on complementary nucleic acid analytes and connecting arrays made of synthetic ones Peptides, their analogs, such as peptoids, oligo-carbamates etc. or generally organic chemical compounds, which are read out by binding to affine protein or other analytes or by enzymatic conversion.
  • Such arrays are currently manufactured according to two different principles by placing the test molecules on already prepared material surfaces: a) by spreading the solution of pre-prepared test compounds once on the surface
  • Previously known chip configurations use either a right-angled x / y arrangement, which is produced with appropriately manufactured photolithography or printing masks, or a circular r ⁇ arrangement, which is generated by a rotational movement of the chip surface (r ⁇ -arrays) and a rapidly clocked metering device becomes. This enables densities of up to 1 million test connections per cm 2 or a few square micrometers per individual surface to be achieved.
  • the invention thus relates to a method for producing stable, regenerable antibody arrays, in which
  • the invention further relates to an antibody array which can be obtained by the method according to the invention, a medical or diagnostic device which has an antibody array according to the invention, and a kit which has an antibody array according to the invention and detection reagents for qualitative or quantitative determination contains bound antigens which have been bound to an antibody array according to the invention.
  • the invention further specifies the use of an antibody array according to the invention or a medical or diagnostic device according to the invention for the qualitative or quantitative determination of antigens.
  • Advantageous and / or preferred embodiments of the invention are the subject of the dependent claims.
  • the planar carrier has a surface made of glass, metal, metal oxides, semimetal oxides or plastic.
  • the antibody binding protein is selected from Fc-specific secondary antibodies, protein A and protein G.
  • the antigen to be determined is a protein.
  • the specific antibodies are "directed” immobilized, i.e. via their Fc part in order not to influence the antigen recognition through the coupling.
  • a grid of proteins that specifically recognize the Fc part of the specific antibodies is covalently bound to the chip surface in question (eg derivatized Fc-specific secondary antibodies or protein A or protein G molecules).
  • Protein / antibody or antibody / antibody complexes are achieved by chemical covalent crosslinking, where be used for common reagents according to the requirements.
  • chemical covalent crosslinking In addition to the stabilization of the protein-protein interactions, there is also an intramolecular stabilization of the specific antibodies, ie a chemical cross-linking of their subunits.
  • Antibody arrays with the highest stability result, which on the one hand prevent dissociation of the special antibodies, eg during storage, and on the other hand also make it possible to treat the antibody arrays under stringent conditions, such as high salt concentrations or low or high pH to prevent non-specific or low affinity interactions with the antibody matrix. This also enables a correspondingly stringent pretreatment of the protein mixtures to be analyzed.
  • the whole process delivers stable and regenerable antibody arrays.

Abstract

L'invention concerne un procédé de production de séries d'anticorps stables, régénérables, caractérisé en ce qu'on utilise des protéines immobilisées liant les anticorps et qui sont capables d'identifier spécifiquement la fraction Fc d'anticorps.
EP02745239A 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables Withdrawn EP1379545A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10119308 2001-04-19
DE10119308 2001-04-19
DE10162365 2001-12-18
DE10162365 2001-12-18
PCT/EP2002/004311 WO2002085926A2 (fr) 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables

Publications (1)

Publication Number Publication Date
EP1379545A2 true EP1379545A2 (fr) 2004-01-14

Family

ID=26009128

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02745239A Withdrawn EP1379545A2 (fr) 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables

Country Status (4)

Country Link
US (1) US20040171068A1 (fr)
EP (1) EP1379545A2 (fr)
JP (1) JP2004536290A (fr)
WO (1) WO2002085926A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
DE602004028445D1 (de) * 2003-02-24 2010-09-16 Pritest Inc Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
EP1797881B1 (fr) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Composition medicamenteuse avec une stabilite amelioree et une tendence de gelification reduite
EP2281901B1 (fr) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
US20090053236A1 (en) 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP2036557B1 (fr) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
CN101460847A (zh) * 2006-06-02 2009-06-17 皇家飞利浦电子股份有限公司 检测分析物的装置和方法
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
JP5319306B2 (ja) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
CN101796197B (zh) 2007-06-08 2014-02-12 比奥根艾迪克Ma公司 预测抗tnf响应性或无响应性的生物标志物
US8952035B2 (en) * 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP5991916B2 (ja) * 2009-05-29 2016-09-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 自己免疫性ｔ細胞の単離および処理のためのペプトイドリガンド
AU2010256880B2 (en) * 2009-06-02 2015-01-22 Opko Health, Inc. Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
TW201124726A (en) * 2009-10-16 2011-07-16 Univ Texas Compositions and methods for producing coded peptoid libraries
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
JP2018506526A (ja) 2015-01-29 2018-03-08 ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティＢｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｍｉｃｈｉｇａｎ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ クリプティックポリペプチドおよびその使用
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
JP2021511389A (ja) 2018-01-25 2021-05-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脊髄性筋萎縮症を治療する方法
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
JP2022512590A (ja) 2018-10-05 2022-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 ソラフェニブ化合物を含む療法のためのバイオマーカー
CN113167798A (zh) 2018-10-05 2021-07-23 卫材R&D管理有限公司 用于包含乐伐替尼和依维莫司的组合疗法的生物标志物
WO2020167715A1 (fr) 2019-02-12 2020-08-20 Biogen Ma Inc. Biomarqueurs de la leucoencéphalopathie multifocale progressive
EP3941474A2 (fr) 2019-03-19 2022-01-26 Incyte Corporation Biomarqueurs pour le vitiligo
US20210123930A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072098A1 (fr) 2019-10-10 2021-04-15 Incyte Corporation Biomarqueurs de la maladie du greffon contre l'hôte
WO2022047419A1 (fr) 2020-08-31 2022-03-03 City Of Hope Nouvelles lignées cellulaires, procédés de production de cellules tueuses naturelles et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
US5620845A (en) * 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit
AU1360297A (en) * 1996-01-11 1997-08-01 Australian Membrane And Biotechnology Research Institute Ion channel sensor typing
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6713309B1 (en) * 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02085926A2 *

Also Published As

Publication number Publication date
JP2004536290A (ja) 2004-12-02
US20040171068A1 (en) 2004-09-02
WO2002085926A2 (fr) 2002-10-31
WO2002085926A3 (fr) 2003-11-06

Similar Documents

Publication Publication Date Title
EP1379545A2 (fr) Procede de production de series d'anticorps stables regenerables
DE19740263C2 (de) Kachelungsverfahren zum Bauen eines chemischen Arrays
DE102009012169B3 (de) Vorrichtung und Verfahren zum Herstellen eines Replikats oder eines Derivats aus einem Array von Molekülen und Anwendungen derselben
DE60126319T2 (de) Immobilisierung von biopolymeren auf aminierten substraten durch direkte adsorption
EP1831690A1 (fr) Supports tridimensionnels a nanostructure et microstructure
EP0706646A1 (fr) Porte-echantillons et son utilisation
WO2005105308A1 (fr) Supports poreux fonctionnalises pour microreseaux
EP1277055B1 (fr) Biopuce pour l'archivage et l'analyse en laboratoire medical d'un echantillon biologique
DE112005003134T5 (de) Elektrisch aktiver kombinatorisch-chemischer (electrically-active combinatorial-chemical; eacc) Chip zur biochemischen Analytbestimmung
DE60213890T2 (de) Reaktionssondenchip und detektionssystem
WO2009049838A2 (fr) Modification de surface
EP1451558A1 (fr) Support de surface de detecteur spr
WO2007140889A1 (fr) Procédé de préparation de macro- et microréseaux parfaits par combinaison de fragments présélectionnés de phases solides revêtues
WO2007059839A9 (fr) Procede, dispositif et trousse pour l'analyse de macromolecules dans un echantillon
DE102004048685A1 (de) Verfahren zum Nachweis von Biopolymeren, Biochips, Verfahren zur Immobilisierung von Antikörpern und Substrate auf denen Antikörper immobilisiert sind
WO2007085403A2 (fr) Supports réticulables multifonction pour ligands (de faible poids moléculaire), leur utilisation en analytique et procédé de production et de réticulation desdits supports
DE102004043870B4 (de) Verfahren zur Erweiterung des dynamischen Erfassungsbereich bei Mikroarrays
DE10126798A1 (de) Verfahren zur Bestimmung einer Probe
EP1477809A1 (fr) Procédé pour imprimer des biomolécules
WO2003046198A2 (fr) Procede de selection et d'identification de molecules peptidiques ou proteiques par presentation a la surface de phages
EP1451319A2 (fr) Procede d'identification de partenaires d'interaction au moyen de l'expression phagique
DE10340429A1 (de) Hydrophober Gegenstand mit Raster hydrophiler Bereiche, dessen Herstellung und Verwendung
DE202006009728U1 (de) Mikroarray-Anordnung, die eine mikroporöse Membran und eine spezifische Inkubationskammeranordnung umfaßt
WO2008080531A2 (fr) Procédé, dispositif et kit pour l'examen d'un échantillon de liquide
DE102007056398A1 (de) Flexibles Extraktionsverfahren für die Herstellung sequenzspezifischer Molekülbibliotheken

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031014

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20050401